Curanex Pharmaceuticals Common Stock Performance
| CURX Stock | 0.37 0.01 2.78% |
The firm shows a Beta (market volatility) of 1.78, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Curanex Pharmaceuticals will likely underperform. At this point, Curanex Pharmaceuticals has a negative expected return of -0.56%. Please make sure to confirm Curanex Pharmaceuticals' information ratio, kurtosis, as well as the relationship between the Kurtosis and period momentum indicator , to decide if Curanex Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Curanex Pharmaceuticals Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in February 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 74.4 K | |
| Free Cash Flow | -555.6 K |
Curanex Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 59.00 in Curanex Pharmaceuticals Common on October 18, 2025 and sell it today you would lose (22.00) from holding Curanex Pharmaceuticals Common or give up 37.29% of portfolio value over 90 days. Curanex Pharmaceuticals Common is currently does not generate positive expected returns and assumes 6.4569% risk (volatility on return distribution) over the 90 days horizon. In different words, 57% of stocks are less volatile than Curanex, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Curanex Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Curanex Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Curanex Pharmaceuticals Common, and traders can use it to determine the average amount a Curanex Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0873
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CURX |
Based on monthly moving average Curanex Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Curanex Pharmaceuticals by adding Curanex Pharmaceuticals to a well-diversified portfolio.
Curanex Pharmaceuticals Fundamentals Growth
Curanex Stock prices reflect investors' perceptions of the future prospects and financial health of Curanex Pharmaceuticals, and Curanex Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Curanex Stock performance.
| Return On Equity | -0.85 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 4.43 M | ||||
| Shares Outstanding | 28.34 M | ||||
| Price To Book | 0.71 X | ||||
| EBITDA | (290.39 K) | ||||
| Total Debt | 14.57 K | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (555.58 K) | ||||
| Earnings Per Share | (0.02) X | ||||
| Total Asset | 517.93 K | ||||
| Retained Earnings | (622.45 K) | ||||
About Curanex Pharmaceuticals Performance
Evaluating Curanex Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Curanex Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Curanex Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Curanex Pharmaceuticals performance evaluation
Checking the ongoing alerts about Curanex Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Curanex Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Curanex Pharmaceuticals generated a negative expected return over the last 90 days | |
| Curanex Pharmaceuticals has high historical volatility and very poor performance | |
| Curanex Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Curanex Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (361.51 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Curanex Pharmaceuticals generates negative cash flow from operations | |
| About 68.0% of the company shares are held by company insiders |
- Analyzing Curanex Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Curanex Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Curanex Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Curanex Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Curanex Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Curanex Pharmaceuticals' stock. These opinions can provide insight into Curanex Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Curanex Stock Analysis
When running Curanex Pharmaceuticals' price analysis, check to measure Curanex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curanex Pharmaceuticals is operating at the current time. Most of Curanex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Curanex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curanex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Curanex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.